In the PROVIDE study, selected predictors such as HAZ at week 18, MPO at week 12, and soluble CD14 at week 18 offer a potential explanation for the burden of malnutrition problems in low-income countries, allow early identification of infants at risk, and suggest pathways for intervention. The gene discussed is MPO; the disease is malnutrition.